Table 1.
Clinical characteristics of the patients included in the meta-analysis
| References | Country | Study design | Total N | Median/mean follow-up |
|---|---|---|---|---|
| Panagopoulos et al. (2001) | Sweden | N/D | 60 | 35 months |
| Mezzelani et al. (2001) | Italy | Consecutive | 72 | N/D |
| Ladanyi et al. (2002) | USA | Retrospective | 242 | 2·7 years |
| Guillou et al. (2004) | Switzerland | Retrospective | 165 | 37 months |
| Takenaka et al. (2008) | Japan | Retrospective | 108 | 54 months |
| ten Heuvel et al. (2009) | Netherlands | N/D | 45 | 55 months |
| Sun et al. (2009) | China | N/D | 141 | 54 months |
| Krieg et al. (2011) | Switzerland | Retrospective | 62 | 11.4 years |
| Charbonneau et al. (2013) | USA | Retrospective | 103 | N/D |
| Ren et al. (2013) | China | Retrospective | 88 | 42·7 months |
| References | Analyzed N | Fusion gene analysis | SS18–SSX1/SS18–SSX2 | Survival analysis |
|---|---|---|---|---|
| Panagopoulos et al. (2001) | 47 | PCR | 31/16 | DSS, MFS |
| Mezzelani et al. (2001) | 64 | PCR | 40/24 | MFS |
| Ladanyi et al. (2002) | 202 | PCR or FISH | 122/80 | OS |
| Guillou et al. (2004) | 141 | PCR | 99/42 | DSS, MFS |
| Takenaka et al. (2008) | 91 | PCR | 57/34 | OS, MFS |
| ten Heuvel et al. (2009) | 45 | PCR or FISH | 27/18 | DSS, MFS |
| Sun et al. (2009) | 141 | PCR | 50/91 | DSS, MFS |
| Krieg et al. (2011) | 43 | PCR | 30/13 | OS |
| Charbonneau et al. (2013) | 40 | PCR | 24/16 | PFS |
| Ren et al. (2013) | 88 | PCR | 47/41 | OS |
N/D not document, N number of patients, PCR reverse transcription-polymerase chain reaction, FISH fluorescent in situ hybridization, OS overall survival, DSS disease-specific survival, PFS progression-free survival, MFS metastasis-free survival.